This book effectively summarizes our knowledge of recent advances in prostate cancer. It focuses on our state-of-the-art understanding of risk factors, prevention, detection, prognosis and treatment of prostate cancer and identifies basic science findings that are being translated into clinical practice. In addition, the book singles out key areas of research that have potential for clinical translation. Both basic scientists and clinicians will be invited to provide up-to-date reviews in each area of prostate cancer.
During the last decade the pace of clinical discovery and the scientific advances in prostate cancer have been very rapid. For instance, currently there are more than 100 drugs in the pharmaceutical pipeline that have the potential for clinical management of prostate cancer. Therefore, it has been very difficult for clinicians and basic scientists to keep pace with the field as a whole. Recently, some of these discoveries are already having an impact on clinical practice. For example, the discovery of the androgen receptor gene amplification in prostate cancer has led to the development of a ¡°super-antiandrogen¡±, which is being tested in clinical trials. Also, recent knowledge of androgen synthesis in prostate cancer cells has led to clinical trials with steroid-metabolism inhibitors. Finally, robotic surgery has also dramatically changed clinical practice. Thus, this important book serves to provide readers with a one-stop overview of the field of prostate cancer research and its translation into the clinical arena.
Readership: Students: Residents in urology; fellows in medical oncology, radiation oncology and cancer biology research; Professionals: Urologists; medical oncologists; radiation oncologists; cancer biology research faculty.
¡öPathology of Prostate (Lawrence True [University of Washington, USA] and Funda Vakar-Lopez [University of Washington, USA])
¡öGenetic Basis for Prostate Cancer (Stacy Loeb [Johns Hopkins Medical Institutions, USA] and William B Isaacs [Johns Hopkins University, USA])
¡öAndrogen Receptor Converts from a Growth Suppressor in the Normal Prostate to an Oncogene in Prostate Cancer (Donald J Vander Griend [The University of Chicago, USA] and John T Isaacs [The Johns Hopkins University, USA])
¡öEtiology: Role of ETS Factor Gene Fusions (Jianghua Wang [Michael E. DeBakey Department of Veterans Affairs Medical Center, USA] and Michael Ittmann [Baylor College of Medicine and Michael E. DeBakey Department of Veterans Affairs Medical Center, USA])
¡öEtiology of Prostate Cancer: Role of Inflammation (William G Nelson [Sidney Kimmel Comprehensive Cancer Center, USA], Angelo M DeMarzo [Johns Hopkins University School of Medicine, USA] and Srinivasan Yegnasubramanian [Sidney Kimmel Comprehensive Cancer Center, USA])
¡öTumor Biology (Elisa Benedettini [Harvard Medical School Boston, USA], Kathryn L Penney [Brigham and Women's Hospital, USA], Michelangelo Fiorentino [Dana Farber Cancer Institute, USA] and Massimo Loda [Harvard Medical School, USA])
¡öThe Androgen Receptor (Kaustubh Datta [Mayo Clinic College of Medicine, USA], Kimberly B Dahlman, Charles L Sawyers [Memorial Sloan-Kettering Cancer Center, USA] and Donald J Tindall [Mayo Clinic College of Medicine, USA])
¡öIntracrine Synthesis of Androgens by Prostate Cancer in Response to Androgen Deprivation Therapy (James L Mohler [Roswell Park Cancer Institute & University of North Carolina at Chapel Hill, USA], Mark A Titus, Alejandro S Godoy [Roswell Park Cancer Institute, USA], Daizo Oka [Osaka University Graduate School of Medicine, Japan] and Peter S Nelson [Fred Hutchinson Cancer Research Center, USA])
¡öGenetically Engineered Mouse Models in Prostate Cancer Research (Fen Wang, Wallace L McKeehan [Texas A&M Health Science Center, USA], Michael M Shen and Cory Abate-Shen [Columbia University Medical Center, USA])
¡öDetection of Prostate Cancer: PSA (Amit Gupta [Memorial Sloan-Kettering Cancer Center, USA], Hans Lilja [Memorial Sloan-Kettering Cancer Center, USA & Lund University, Sweden] and Fritz H Schroeder [Erasmus University Rotterdam, The Netherlands])
¡öImaging of Prostate Cancer (Esther Mena, Baris Turkbey, Karen Kurdziel and Peter L Choyke [National Institutes of Health, USA])
¡öRole of Nomograms in the Management of Prostate Cancer (Andrew J Stephenson, Carvell T Nguyen and Michael W Kattan [Cleveland Clinic, USA])
¡öDecision Points and Results of Radiotherapy by Prostate Cancer Risk Group (Dayssy Alexandra Diaz [University of Miami/Jackson Memorial Hospital, USA] and Alan Pollack [University of Miami, USA])
¡öTreatment of Prostate Cancer: Surgery (Vincent P Laudone [Memorial Sloan Kettering Cancer Center, USA], Bertrand D Guillonneau [GH Diaconesses ¡ª Croix St. Simon, France], Karim A Touijer and James A Eastham [Memorial Sloan Kettering Cancer Center, USA])
¡öTreatment of Prostate Cancer ¡ª Hormonal Therapy (Aymen Elfiky and Philip Kantoff [Harvard Medical School, USA])
¡öChemotherapy for Castration-Resistant Prostate Cancer (Gopa Iyer, Howard I Scher and David B Solit [Memorial Sloan-Kettering Cancer Center, USA])
¡öNovel Therapeutic Approaches to Advanced Prostate Cancer (Matthew K Tollefson and Eugene D Kwon [Mayo Clinic, USA])
¡öPrevention of Prostate Cancer: A Focus on Completed Clinical Trials and a Vision of the Future (John P Fitzgerald, Melissa Talbert and Ian Thompson [University of Texas Health Science Center at San Antonio, USA])